BRWM
PSTV

B. Riley Wealth Management’s Plus Therapeutics PSTV Stock Holding History

B. Riley Wealth Management’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-32
Closed -$29K – 460
2021
Q1 		$29K Buy
+32
New +$32.4K ﹤0.01% 428

Other funds holding PSTV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

B. Riley Wealth Management's PSTV Position: Q2 2021 in Review

B. Riley Wealth Management sold out of Plus Therapeutics (PSTV) in Q2 2021, closing a stake of 32 shares — an estimated $29K sold.

B. Riley Wealth Management first reported a position in PSTV in Q1 2021 and held it in 1 quarter. The position peaked at $29K in Q1 2021. 14 funds tracked by Wall St. Rank hold PSTV as of Q2 2021.

  • B. Riley Wealth Management reported no remaining Plus Therapeutics position as of Q2 2021 after selling out during the quarter.
  • B. Riley Wealth Management sold 32 Plus Therapeutics shares in Q2 2021, an estimated $29K.
  • B. Riley Wealth Management first reported a position in Plus Therapeutics in Q1 2021 and held it in 1 quarter.
  • B. Riley Wealth Management's Plus Therapeutics position peaked at $29K in Q1 2021.
  • 14 funds tracked by Wall St. Rank held Plus Therapeutics as of Q2 2021.

Based on B. Riley Wealth Management's 13F filing for Q2 2021, filed 12 Aug 2021.